Retinal Vein Occlusion
Retinal Vein Occlusion Market

Retinal Vein Occlusion is a blockage of the small veins, which carry blood away from the retina. The retina is the layer of tissue at the back of the inner eye, which converts light images to nerve signals and sends them to the brain. 


Retinal Vein Occlusion Epidemiological Segmentation 

The Epidemiological Segmentation of Retinal Vein Occlusion in 7MM from 2017 to 2030 is segmented as:- 

  • Total Prevalent Cases of Retinal Vein Occlusion 
  • Total Diagnosed Prevalent cases of Retinal Vein Occlusion 
  • Gender-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion
  • Age-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion
  • Type-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion
  • Treated cases of Retinal Vein Occlusion


Retinal Vein Occlusion Epidemiology 

  • The total prevalent cases of Retinal Vein Occlusion in 7MM in 2017 were 2,225,011  
  • The total prevalent cases of Retinal Vein Occlusion in the United States in 2017 were 1,124,718   
  • EU5 countries occupied 33.53% of the patient pool amongst 7MM in 2017 
  • The treated cases of Retinal Vein Occlusion in the United States in 2017 were 860,409 


Retinal Vein Occlusion Market

The market size of Retinal Vein Occlusion in 7MM in 2017 was USD 2,127.70 Million 

  

Retinal Vein Occlusion Market Drivers

  • Rich Pipeline
  • Advancement in Drug therapies 
  • Increase in knowledge and awareness
  • Increasing Prevalence of Retinal Vein Occlusion 
  • Increasing use of biologics


Retinal Vein Occlusion Market Barriers

  • Cost Consciousness
  • Risk and complications
  • Lack of focus on for visual restoration
  • Failure of Investigational Drugs
  • Invasion of Biosimilars in future 


Retinal Vein Occlusion Emerging Drugs

The emerging drugs of the Retinal Vein Occlusion market are 

  • Brolucizumab (RTH258/ESBA1008)
  • TLC399 (ProDex)
  • AR-1105
  • GB-102
  • ONS-5010/LYTENAVA (bevacizumab)
  • Bevacizumab

And many others. 


Retinal Vein Occlusion Key Players

The key players in the Retinal Vein Occlusion market are

  • Novartis Pharmaceuticals
  • Taiwan Liposome Company
  • Aerie Pharmaceuticals
  • Graybug Vision
  • Outlook Therapeutics
  • The Emmes Company

And many others.